

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE PROPOSED CHANGE OF AUDITORS

Reference is made to the announcement of Giant Biogene Holding Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 April 2026 (the “**Announcement**”) and the circular of the Company dated 6 May 2026 in relation to the proposed change of auditors (the “**Circular**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement and the Circular.

The Board would like to provide the following supplementary information in relation to the proposed change of auditors of the Company.

CHRONOLOGY OF EVENTS IN RELATION TO THE PROPOSED CHANGE OF AUDITORS

In the end of March 2026, a meeting of the Audit Committee was held, during which the management of the Company considered the tenure of EY as the Group’s auditors, having regard to good corporate governance practices.

After considering the above matters, between early and mid-April 2026, the Company commenced the search for new auditor. A series of discussions and meetings were held among the Audit Committee, the Company and KPMG with a view to gaining understanding on the Group’s operations, as well as conducting preliminary assessment on the potential auditor.

On 21 April 2026, the management of the Company provided the collated audit proposal and supporting materials of KPMG to the Audit Committee for its review and consideration, under which KPMG was assessed against pre-determined evaluation criteria, including but not limited to, governance and leadership, experience, industry knowledge and technical competence, independence and objectivity, resources and capabilities, audit proposal and audit fee. After reviewing the proposal, the Audit Committee noted that KPMG (i) has an experienced and well-structured engagement team with sufficient resources, (ii) has a sufficient number of clients listed on the Stock Exchange, and (iii) is capable of undertaking the Group's audit in compliance with the applicable auditing and independence requirements. The Audit Committee's preliminary view was that the appointment of KPMG would be in the best interests of the Company and its Shareholders as a whole. Accordingly, on 22 April 2026, the Company held discussions with EY on its retirement in order to facilitate the appointment of the new auditor.

On 28 April 2026, the Audit Committee held a meeting with EY, to discuss, among other things, the observance of good corporate governance practices under the Listing Rules, having regard to the fact that EY has audited the consolidated financial statements of the Group for seven consecutive financial years up to and including the year ended 31 December 2025.

On 30 April 2026, EY tendered its resignation letter to the Company. The Audit Committee, after having discussion with EY, was satisfied that all underlying reasons leading to the resignation of EY have been disclosed in the Announcement. On the same date, the Board, after due consideration and with the recommendation of the Audit Committee, has resolved to appoint KPMG as the auditors of the Company for the year ending 31 December 2026, subject to the approval by the Shareholders at the AGM.

THE AUDIT COMMITTEE'S ASSESSMENT ON KPMG

As disclosed in the Circular, the Audit Committee has considered the relevant sections of the AFRC's guidance in assessing the appointment of KPMG as the new auditor of the Company. In particular, the Audit Committee obtained and reviewed the 2024–25 AFRC's Annual Inspection Report publicly issued by AFRC (the "**Report**"). The Report disclosed that KPMG is a Category A registered firm with satisfactory inspection results. With reference to the inspection results in the Report and the best knowledge of the Audit Committee, the Audit Committee is not aware of any behavior or activities from KPMG that will threaten the integrity, objectivity and independence or adversely affect its quality of audit.

THE AUDIT PLANNING AND TIMETABLE OF KPMG FOR THE AUDIT

EY has completed the audit of the consolidated financial statements of the Group for the year ended 31 December 2025 in March 2026, and has not commenced any audit work on the consolidated financial statements of the Group for the year ending 31 December 2026.

Proposed audit timetable

As the proposed change of auditor is not close to financial year end, KPMG has sufficient time to plan and perform the audit work for the year ending 31 December 2026. KPMG's proposed audit plan and timetable for the audit of the Group's consolidated financial statements for the year ending 31 December 2026 are set out as follows:

Phase	Period	Key procedures and events
Planning and interim review	July to August 2026	<ul style="list-style-type: none">(i) Implement the transition plan(ii) Plan and perform the interim review(iii) Perform risk assessments(iv) Meet with the management of the Company to discuss key issues upfront
Control evaluation and focused approach	October 2026 to December 2026	<ul style="list-style-type: none">(i) Plan the final audit(ii) Perform the control evaluation and respective control testing work(iii) Discuss and resolve key issues with the management of the Company before year end(iv) Meet with the Audit Committee to present audit plan
Final audit fieldwork	January 2027 to March 2027	<ul style="list-style-type: none">(i) Commence final audit fieldwork(ii) Perform substantive work(iii) Meet with the management of the Company to discuss and resolve issues, and report observations and recommendations
Reporting and evaluation	March 2027	<ul style="list-style-type: none">(i) Complete the final audit for consolidation(ii) Meet with the Audit Committee to report audit findings(iii) Issue audit opinion(iv) Meet with the management of the Company for evaluation and debriefing

Team Structure of KPMG

KPMG has provided their time budgets and estimated hours for the engagement and is committed to deploying an experienced team comprising two principal engagement audit partners, one engagement quality control review partner, one senior manager, one manager and a dedicated core audit team of six team members, supported by a team of specialists covering areas including IT, taxation, accounting, capital markets, valuation etc.. Based on the foregoing and the information disclosed in the Circular, the Audit Committee is satisfied that KPMG is independent, competent and capable to perform a high-quality audit for the Company.

KPMG has confirmed its commitment to fulfilling the proposed audit timetable while maintaining audit quality, by allocating sufficient resources efficiently and ensuring the direct involvement of senior engagement personnel in audit planning, supervision and review, having regard to the nature, scope and complexity of the Group's businesses.

Having regard to the foregoing, the Audit Committee is satisfied that the proposed audit strategy, audit plan and timetable are reasonable and adequate for the KPMG to complete all necessary audit procedures without compromising audit quality, and that KPMG's committed resources are sufficient to support the audit engagement.

All other information contained in the Announcement and the Circular remain unchanged and continue to be valid for all purposes. This announcement is supplemental to and should be read in conjunction with the Announcement and the Circular.

By Order of the Board
Giant Biogene Holding Co., Ltd
YAN Jianya
Chairman of the Board

Xi'an, the PRC, 28 May 2026

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive Directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive Directors.